Dogwood Therapeutics secures $5 million private placement from top shareholder Sealbond

Dogwood Therapeutics, Inc. (Nasdaq: DWTX) announced on October 19, 2026 that it entered a securities subscription agreement with Sealbond Limited, a subsidiary of CK Life Sciences Int'l., (Holdings) Inc., for a $5 million investment. The agreement covers an investment from the company's largest shareholder, a subsidiary of CK Life Sciences Int'l., (Holdings) Inc.¹

Under the terms, Dogwood will issue an aggregate of 4,098,360 shares of Common Stock at a price of $1.22 per share.¹ The private placement is being priced at-the-market under Nasdaq rules, and no warrants or other derivative securities are included in the transaction.¹ The deal is expected to close on or prior to October 29, 2026.¹

Before the transaction, Sealbond held about 63.9% of Dogwood's outstanding common stock and is treated as an affiliate of the company.¹

The company said proceeds will support Phase 3 preparatory activities and extend its operational runway through March 2027.¹ Separately, the 8-K discloses a related registration rights agreement: Dogwood must file a registration statement for the shares no later than 15 days after the agreement's date, and use reasonable best efforts to have it declared effective as soon as practicable, generally no later than five business days after SEC clearance.¹

The financing comes as Dogwood continues its Phase 2b trial of Halneuron in chemotherapy-induced neuropathic pain. The randomized HAL-CINP trial (NCT06848348) is testing Halneuron against placebo in 239 patients with moderate to severe neuropathic pain from prior platinum and/or taxane-based chemotherapy, with participants receiving eight subcutaneous doses over 14 days and followed for 28 days; the primary endpoint is change from baseline to week four in weekly average pain intensity scores, and the trial is being conducted at about 25 U.S. sites.¹ Topline data from this trial are expected in November 2026.¹